Bayesian Capital Management’s PAVmed PAVM Stock Holding History

Bayesian Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-91	Closed	-$54K	–	999
2022 Q1	$54K	Buy	+91	New	+$67.6K	0.01%	731

Other funds holding PAVM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's PAVM Position: Q2 2022 in Review

Bayesian Capital Management sold out of PAVmed (PAVM) in Q2 2022, closing a stake of 91 shares — an estimated $54K sold.

Bayesian Capital Management first reported a position in PAVM in Q1 2022 and held it in 1 quarter. The position peaked at $54K in Q1 2022. 73 funds tracked by Wall St. Rank hold PAVM as of Q2 2022.

Bayesian Capital Management reported no remaining PAVmed position as of Q2 2022 after selling out during the quarter.
Bayesian Capital Management sold 91 PAVmed shares in Q2 2022, an estimated $54K.
Bayesian Capital Management first reported a position in PAVmed in Q1 2022 and held it in 1 quarter.
Bayesian Capital Management's PAVmed position peaked at $54K in Q1 2022.
73 funds tracked by Wall St. Rank held PAVmed as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.